DTIL
PRECISION BIOSCIENCES INC
NASDAQ · Healthcare · Biotechnology · US
$6.67
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.66
From 52W high−28.13%
Volume237326.00
Market cap$184.10M
P/E (TTM)—
P/S (TTM)4.1x
Div yield—
Key dataSep 18, 2026
Open
$6.66
From 52W high
−28.13%
Volume
237326.00
Market cap
$184.10M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
29.9
MomentumView details →
1D Return
+0.00%
YTD Return
+58.41%
SummaryUpdated Jun 1, 2026
Precision BioSciences, Inc. (NASDAQ:DTIL) is a clinical-stage biotechnology company founded in 2006 and headquartered in Durham, North Carolina. The company went public in March 2019 and focuses on developing advanced gene editing therapies to treat genetic disorders and cancer. Precision BioSciences operates at the cutting edge of biotechnology, utilizing proprietary gene editing platforms to create both in vivo therapies that work directly within patients' bodies and ex vivo treatments that modify cells outside the body before reintroduction.
Similar companies
Latest newsMore news →
Precision BioSciences reported its financial results for the second quarter ended June 30, 2026, and provided a business update on August 6, 2026.45d agoPrecision BioSciences Inc announced that Alex Kelly will step down as Chief Operating Officer effective August 1, 2026, and Naresh Tanna will succeed him as Chief Financial Officer effective the same date.56d ago